Clinical Trial Update: The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer

View source ↗

Summary

A clinical trial update evaluating the value of the 68Ga-grazytracer PET imaging tracer in guiding immunotherapy for stage III non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• 68Ga-grazytracer

Snippet

Sponsor: Ruijin Hospital | Conditions: Carcinoma, Non-Small-Cell Lung, PET / CT | Status: RECRUITING